Process for the preparation of lacosamide

This application is a 371 of PCT/IB2010/056014, filed Dec. 22, 2010.

The present invention relates to a novel process for the preparation of (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide, an active ingredient used for curing neuropathies, known by the name of Lacosamide and represented by the formula of structure I indicated below

The process according to the present invention is carried out starting from D,L-serine methylester, i.e. the molecule with the formula of structure II indicated below,

which is preferably used in the form of hydrochloride.

Alternatively, it can be carried out starting from the acetamide of D,L-serine methylester, i.e. the molecule corresponding to the formula of structure III, also indicated below:

Lacosamide is an active ingredient used in the pain therapy and for curing various diseases of the nervous system among which epilepsy. Though the action mechanism is not completely clear, it seems that it operates on the sodium channels of the neurons reducing their activity. Furthermore, Lacosamide is thought to be involved in the restoration of the damaged neurons.

The product is described and claimed in the U.S. Pat. No. RE38,551. Three different synthesis methods which use D-serine as starting material and methyl iodide and silver oxide for the methylation of the OH are also indicated in this document. An alternative method for the synthesis of Lacosamide is that described in the patent application WO 2006/037574 where, starting from N-Boc protected D-serine, the methylation reaction of hydroxyl is carried out using butyllithium and an alkylating agent.

A further alternative synthesis method is that indicated in the patent application EP 2067765 where, before the methylation of hydroxyl, the amino group is protected with a hindered group such as the trityl.

All the preparation methods described up to now use D-serine as starting material and use expensive reagents such as silver oxide or butyllithium or hindered protective groups with the aim of minimising the racemisation of the product. The reason lies in the fact that methods for the resolution of racemic mixtures of Lacosamide have not yet been developed up to date and the purification of the R enantiomer is described as extremely difficult.

The present invention relates to a novel synthesis of Lacosamide which uses D,L-serine as starting material, where the methylation reaction of hydroxyl is carried out using an inexpensive base such as NaOH and an inexpensive alkylating agent, non-toxic and non-carcinogenic, such as the methyl p-toluenesulfonate; the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the acetamide, salification of the racemic mixture with a chiral acid (HX*) in an organic solvent, resolution of the diastereoisomeric mixture, preferably by precipitation of the R enantiomer, and subsequent acetylation of the optically pure intermediate.

The present invention relates to a novel synthesis of Lacosamide which uses D,L-serine methyl ester, of formula II, as starting material, preferably in the form of hydrochloride, easily obtainable from D,L-serine by the extensively described methods.

The product of formula II is converted into the product of formula V by reaction first using benzylamine and subsequently using acetic anhydride (or an acetyl halide, preferably acetyl chloride, or using a mixed anhydride), according to the following scheme.

The first reaction is preferably carried out directly in benzylamine (from 2 to 10 equivalents), or in an aprotic polar solvent, such as for example THF, at a temperature comprised between 0° C. and the reflux temperature, preferably at 30-40° C.; the second reaction is carried out by reacting the compound IV with acetic anhydride (or with an acetyl halide, preferably acetyl chloride) in an aprotic polar solvent, such as for example THF, at a temperature preferably comprised between 10 and 40° C., preferably between 15 and 30° C., even more preferably between 20 and 25° C.

Alternatively the compound V can be prepared from the D,L-serine methyl ester acetamide of formula III, available in the market, by reaction with benzylamine; also in this case the reaction is preferably carried out directly in benzylamine (from 2 to 10 equivalents), or in a suitable organic solvent, preferably an aprotic polar solvent, such as for example THF, at a temperature comprised between 0° C. and the reflux temperature of the solvent, preferably at about 65° C.

The compound V is converted into the compound VI by methylating the hydroxyl present in the molecule.

The methylation reaction can be carried out by dissolving the compound V in a suitable organic solvent and placing it at contact with an alkylating agent in the presence of an organic or inorganic base, at a temperature preferably comprised between 20 and 40° C., preferably between 30 and 35° C. The solvent is preferably an aprotic polar solvent, such as for example THF. The alkylating agent is preferably selected from among methyl iodide, dimethyl sulfate, methyl mesylate and methyl para-toluenesulfonate; it is preferably methyl para-toluenesulfonate. The organic base is preferably selected from among tertiary amines NR 1 R 2 R 3 , where R 1 , R 2 and R 3 the same or different from each other, are linear or branched C 1 -C 4 alkyl chains; the preferred tertiary amine is triethylamine. The inorganic base is preferably a hydroxide of an alkaline-earth or alkaline metal, such as KOH or NaOH.

The inorganic base can be used in aqueous solution. In case of the use of an inorganic base, it is preferable to use also a phase transfer catalyst for accelerating the reaction; said phase transfer catalyst is preferably a salt of tetrabutylammonium having hydroxide, hydrogen sulfate, chlorine, bromine or iodine as the counterion.

The compound VI, racemic Lacosamide, is converted into the compound VII by hydrolysis in aqueous solution with an inorganic mineral acid, preferably HCl, at a pH preferably comprised between 0 and 2; such hydrolysis reaction is preferably carried out at the reflux temperature. The compound VII is then extracted, after the neutralization of the acid, in an organic solvent, preferably in an aprotic apolar solvent, such as for example CH 2 Cl 2 , CHCl 3 or C 2 H 4 Cl 2 .

The compound VII is then precipitated as salt VIII with a chiral acid (HX*), preferably D, such as for example dibenzoyl tartaric, tartaric, camphorsulfonic, mandelic, 2-chloromandelic, 3-chloromandelic, 4-chloromandelic acid; for the purposes of the present invention, the acid is preferably 2-chloromandelic, even more preferably 2-(S)-chloromandelic acid. The chiral acid is used at an amount preferably comprised between 0.5 and 1.5 equivalents. The precipitation is preferably carried out in an aprotic polar organic solvent, such as for example ethyl acetate or isopropyl acetate, even more preferably isopropyl acetate. The salt VIII quantitatively precipitates from this solvent as a diastereoisomeric mixture. The salt VIII thus obtained is further solubilised in a suitable mixture of solvents capable of allowing selective precipitation of only one enantiomer, preferably the desired enantiomer IX alone. Such mixture of solvents is constituted by an aprotic organic solvent and a protic solvent. The aprotic organic solvent is preferably selected from among THF, methyl-THF, ethyl acetate, isopropyl acetate; aprotic polar organic solvents, such as ethyl acetate and isopropyl acetate are however preferred. The protic solvent is instead preferably selected from among C 1 -C 4 alcohols (for example, methanol, ethanol, isopropanol, n-butanol, i-butanol, s-butanol) and water; preferably, a mixture of ethyl acetate and ethanol is used. According to a further preferred aspect of the invention, 10 to 40 volumes of aprotic organic solvent per volume of protic solvent are used.

The compound IX is acetylated in the presence of an acylating agent in a suitable organic solvent, preferably apolar aprotic, even more preferably an ether, in the presence of an amount of water comprised between 0 and 50% by weight with respect to the compound IX, preferably between 5 and 20%, to obtain Lacosamide. The C 2 -C 8 ethers, such as for example the methyl tert-butyl ether, are particularly preferred for the purposes of the present invention; the acetic anhydride is the preferred acylating agent (alternatively an acetyl halide, preferably acetyl chloride, can be used); the acylation reaction is preferably carried out between 0 and 40° C., preferably between 20 and 25° C. Further objects of the present invention, are represented by the salts of formula VIII and IX

where HX* has the previously listed meanings and, in the preferred aspect of the invention, it is 2-(S)-chloro-mandelic acid.

The complete scheme of the process according to the present invention is indicated in FIG. 1 with reference to the case in which the chiral acid HX* is 2-(S)-chloro-mandelic acid.